Pharma BD Deal Intelligence
Italfarmaco S.p.A. / Iktos
2024 · Co-Development · Complete
Italfarmaco and Iktos entered a collaboration to design next-generation HDAC inhibitors for non-oncological diseases including CNS disorders, applying Iktos's Makya generative drug-design platform and Spaya retrosynthesis platform to Italfarmaco's candidate target profile. Financial terms were not disclosed.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.
Key facts
- Announced Jun 18, 2024
- Deal type Co-Development
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2024 deals